Q1 2026 Relmada Therapeutics Inc Earnings Call Transcript

May 12, 2026 / 08:30 PM GMT

Release Date Price: $7.45 (+1.22%)

Transcript 8-K10-Q

Key Points

Positve

Relmada Therapeutics Inc (RLMD) reported robust 12-month data for NDV01 in non-muscle invasive bladder cancer (NMIBC), demonstrating high response rates and durable efficacy.
The company successfully completed a $160 million private placement financing, strengthening its financial position.
Relmada Therapeutics Inc (RLMD) achieved FDA alignment for its planned Phase III rescue program, enhancing the likelihood of regulatory approval.
A provisional patent application was filed for NDV01, potentially extending patent protection to 2047, which could significantly expand global IP protection.
The company has a strong cash balance of $234 million, expected to fund operations through 2029, including the completion of the Phase III Rescue Program for NDV01.

Negative

Research and development expenses decreased by $3.9 million compared to the previous year, which may indicate reduced investment in new projects.
General and administrative expenses increased by $5.1 million, primarily driven by higher compensation costs.
The net loss for the first quarter of 2026 was $19.1 million, an increase from the previous year's net loss of $17.6 million.
The company faces potential risks and uncertainties associated with forward-looking statements, which could impact future results.
There is a potential for variability or dilution of efficacy in the Phase III trial due to broad inclusion criteria, which could affect trial outcomes.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

RLMD.OQ - Relmada Therapeutics Inc
Q1 2026 Relmada Therapeutics Inc Earnings Call
May 12, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to RELmada Therapeutics First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

After the prepared remarks, we'll conduct a question-and-answer session. To ask a question, please press star one. As a reminder, this conference call is being recorded and will be available for replay on the RELMADA website. I would now like to turn the call over to Brian Ritchie from LifeSci Advisors. Please go ahead, Mr. Ritchie.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good day, everyone, and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.